Ana Rovira

Dr. Ana Rovira

Hospital del Mar Medical Research Institute (IMIM), Barcelona 08003, Spain
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2018 in Genome Medicine
Verified
Journal Article
Open access
PDF file
DTDavid Tamborero
David Tamborero
CRCarlota Rubio-Perez
Carlota Rubio-Perez
JDJordi Deu-Pons
Jordi Deu-Pons
MSMichael P. Schroeder
Michael P. Schroeder
AVAna Vivancos
Ana Vivancos
NLNuria Lopez-Bigas
Nuria Lopez-Bigas
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. The results are organized in different levels of evidence according to current knowledge, which we envision can support a broad range of oncology use cases. The resource is publicly available at http://www.cancergenomeinterpreter.org .

22 January 2012 in Nature Medicine
Verified
Journal Article
Closed access
CMClara Montagut
Clara Montagut
ADAlba Dalmases
Alba Dalmases
BBBeatriz Bellosillo
Beatriz Bellosillo
MCMarta Crespo
Marta Crespo
SPSilvia Pairet
Silvia Pairet
JAJoan Albanell
Joan Albanell

30 April 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SASabrina Arena
Sabrina Arena
BBBeatriz Bellosillo
Beatriz Bellosillo
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
AMAlejandro Martínez
Alejandro Martínez
ICIsrael Cañadas
Israel Cañadas
CMClara Montagut
Clara Montagut
Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment, the molecular landscape of resistant tumors must be ascertained. We investigated the role of mutations in the EGFR signaling axis on the acquisition of resistance to cetuximab in patients and cellular models. Experimental Design: Tissue samples were obtained from 37 patients with colorectal cancer who became refractory to cetuximab. Colorectal cancer cells sensitive to cetuximab were treated until resistant derivatives emerged. Mutational profiling of biopsies and cell lines was performed. Structural modeling and functional analyses were performed to causally associate the alleles to resistance. Results: The genetic profile of tumor specimens obtained after cetuximab treatment revealed the emergence of a complex pattern of mutations in EGFR, KRAS, NRAS, BRAF, and PIK3CA genes, including two novel EGFR ectodomain mutations (R451C and K467T). Mutational profiling of cetuximab-resistant cells recapitulated the molecular landscape observed in clinical samples and revealed three additional EGFR alleles: S464L, G465R, and I491M. Structurally, these mutations are located in the cetuximab-binding region, except for the R451C mutant. Functionally, EGFR ectodomain mutations prevent binding to cetuximab but a subset is permissive for interaction with panitumumab. Conclusions: Colorectal tumors evade EGFR blockade by constitutive activation of downstream signaling effectors and through mutations affecting receptor–antibody binding. Both mechanisms of resistance may occur concomitantly. Our data have implications for designing additional lines of therapy for patients with colorectal cancer who relapse upon treatment with anti-EGFR antibodies. Clin Cancer Res; 21(9); 2157–66. ©2015 AACR.

1 January 2003
Verified
Book Chapter
Closed access
PDF file
JAJoan Albanell
Joan Albanell
JCJordi Codony
Jordi Codony
ARAna Rovira
Ana Rovira
BMBegoña Mellado
Begoña Mellado
PGPere Gascón
Pere Gascón

9 September 2011 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
FRFederico Rojo
Federico Rojo
JGJ. García-Parra
J. García-Parra
SZS. Zazo
S. Zazo
ITI. Tusquets
I. Tusquets
JFJ. Ferrer-Lozano
J. Ferrer-Lozano
JAJ. Albanell
J. Albanell
Poly(ADP-ribose)polymerase-1 (PARP-1) is a highly promising novel target in breast cancer. However, the expression of PARP-1 protein in breast cancer and its associations with outcome are yet poorly characterized. Quantitative expression of PARP-1 protein was assayed by a specific immunohistochemical signal intensity scanning assay in a range of normal to malignant breast lesions, including a series of patients (N = 330) with operable breast cancer to correlate with clinicopathological factors and long-term outcome. PARP-1 was overexpressed in about a third of ductal carcinoma in situ and infiltrating breast carcinomas. PARP-1 protein overexpression was associated to higher tumor grade (P = 0.01), estrogen-negative tumors (P < 0.001) and triple-negative phenotype (P < 0.001). The hazard ratio (HR) for death in patients with PARP-1 overexpressing tumors was 7.24 (95% CI; 3.56–14.75). In a multivariate analysis, PARP-1 overexpression was an independent prognostic factor for both disease-free (HR 10.05; 95% CI 5.42–10.66) and overall survival (HR 1.82; 95% CI 1.32–2.52). Nuclear PARP-1 is overexpressed during the malignant transformation of the breast, particularly in triple-negative tumors, and independently predicts poor prognosis in operable invasive breast cancer.

22 January 2018 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
SGSylwia Gawrzak
Sylwia Gawrzak
LRLorenzo Rinaldi
Lorenzo Rinaldi
SGSara Gregorio
Sara Gregorio
Enrique Javier ArenasEnrique Javier Arenas
Enrique Javier Arenas
FSFernando Salvador
Fernando Salvador
RGRoger R. Gomis
Roger R. Gomis